Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Third-quarter financial results of Boston Scientific announced

Boston Scientific Corporation today announced financial results for the third quarter ended September 30, 2009, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter and full year 2009.

20 Oct 2009

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

AbbeyMoor Medical Inc. announced today they have been granted a Category I CPT code by the American Medical Association (AMA) for The Spanner(TM) temporary prostatic stent insertion procedure. This important action, effective in January 2010, upgrades The Spanner from a Category III emerging technology procedure code to a Category I procedure code for established procedures.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

Renal artery stenosis does not necessitate surgical procedures

Some invasive procedures that are becoming increasingly common as a first line of treatment for patients diagnosed with narrowed arteries in and around the kidneys may not be necessary, according to a new study by researchers at Wake Forest University Baptist Medical Center.

14 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Endologix defends patent infringement lawsuit

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit.

14 Oct 2009

Novasys Medical's Renessa named the most promising new product for 2009

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Patient outcomes better in highly rated hospitals than others

The largest annual study of patient outcomes at each of the nation's 5,000 nonfederal hospitals found a wide gap in quality between the nation's best hospitals and all others. According to the study, issued today by HealthGrades, the leading independent healthcare ratings organization, patients at highly rated hospitals have a 52 percent lower chance of dying compared with the U.S. hospital average, a quality chasm that has persisted for the last decade even as mortality rates, in general, have declined.

13 Oct 2009

Medtronic launches Captivia Delivery System for Valiant Thoracic Stent Graft

Adding to its market-leading portfolio of innovative medical technology for endovascular aortic repair (EVAR), Medtronic, Inc., announced today the CE (Conformité Européene) mark and international launch of the Captivia Delivery System for the Valiant Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta.

9 Oct 2009

Cook Medical files lawsuit against Endologix for patent infringement

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, acknowledged today that it has become aware that Cook Medical has filed a lawsuit against Endologix in the United States District Court alleging that Endologix infringes two of Cook's U.S. patents.

9 Oct 2009

Cook claims infringement of its endovascular stent-grafts patents, sues Endologix

In a move aimed at protecting its worldwide market-leading technology for endovascular repair of aortic aneurysms (EVAR), Cook Incorporated has filed a complaint with the U.S. District Court, Southern District of Indiana, against Endologix, Inc. claiming infringement of two critical patents for endovascular stent-grafts.

9 Oct 2009

Quest Diagnostics' DNA testing for gene variants help improve outcomes for stent recipients

DNA testing for gene variants that can increase the risk of major coronary events in certain patients taking the anti-clotting drug Plavix® (clopidogrel bisulfate) is now being performed by Quest Diagnostics for Scripps Health patients electing to undergo coronary stent procedures.

From Quest Diagnostics 8 Oct 2009

DATATRAK International to evaluate treatment of peripheral vascular disease

DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a new client with the award of a study for evaluating the use of a thoracic stent graft in aneurysm repair.

8 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

New embolization technique offers better clinical outcomes in the treatment of liver cancer

The authors of a newly published paper in the September/October journal Vascular Disease Management conclude that the micro-bland embolization technique possible with Embozene(TM) Color-Advanced Microspheres leads to better clinical outcomes.

6 Oct 2009

HCRI commences patient enrollment in dual antiplatelet therapy study

The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

3 Oct 2009

Society of Interventional Radiology offers intensive five-day course

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice.

1 Oct 2009